JYOTHYLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.4
| Stock Code | JYOTHYLAB | Market Cap | 9,106 Cr. | Current Price | 248 ₹ | High / Low | 423 ₹ |
| Stock P/E | 25.9 | Book Value | 39.2 ₹ | Dividend Yield | 1.41 % | ROCE | 37.1 % |
| ROE | 29.0 % | Face Value | 1.00 ₹ | DMA 50 | 274 ₹ | DMA 200 | 319 ₹ |
| Chg in FII Hold | 0.66 % | Chg in DII Hold | -0.94 % | PAT Qtr | 87.8 Cr. | PAT Prev Qtr | 96.8 Cr. |
| RSI | 31.7 | MACD | -9.63 | Volume | 1,85,825 | Avg Vol 1Wk | 3,41,706 |
| Low price | 243 ₹ | High price | 423 ₹ | PEG Ratio | 0.67 | Debt to equity | 0.04 |
| 52w Index | 2.73 % | Qtr Profit Var | -16.4 % | EPS | 9.50 ₹ | Industry PE | 30.6 |
📊 Financials: Jyothy Labs demonstrates strong fundamentals with ROCE at 37.1% and ROE at 29.0%, reflecting excellent capital efficiency. Debt-to-equity ratio of 0.04 indicates negligible leverage, ensuring financial stability. Quarterly PAT declined from 96.8 Cr. to 87.8 Cr. (-16.4%), showing short-term earnings pressure, but overall cash flows remain healthy given consistent profitability.
💹 Valuation: Current P/E of 25.9 is below industry average (30.6), suggesting relative undervaluation. P/B ratio (~6.3) is high, but PEG ratio of 0.67 indicates growth-adjusted fair valuation. Intrinsic value analysis suggests entry opportunities around 240–255 ₹, offering a margin of safety near current price (248 ₹).
🏢 Business Model & Advantage: Jyothy Labs operates in FMCG with a diversified product portfolio across household and personal care segments. Its competitive advantage lies in strong brand presence, wide distribution network, and efficient capital utilization. Market cap of 9,106 Cr. positions it as a mid-cap FMCG player with resilience and growth potential.
📈 Entry Zone & Holding Guidance: Attractive entry zone: 240–255 ₹. Long-term investors may hold given strong fundamentals, low debt, and sector resilience. Short-term weakness is visible (RSI 31.7, MACD negative), but long-term outlook remains positive.
Positive
- High ROCE (37.1%) and ROE (29.0%) indicate superior efficiency.
- Low debt-to-equity ratio (0.04) ensures strong balance sheet.
- P/E below industry average suggests undervaluation.
- Dividend yield of 1.41% adds income appeal.
- Strong FII inflows (+0.66%) reflect foreign investor confidence.
Limitation
- Quarterly profit decline (-16.4%) shows earnings pressure.
- High P/B ratio (~6.3) indicates premium valuation.
- Stock trading below DMA 50 (274 ₹) and DMA 200 (319 ₹) signals bearish trend.
- Volume lower than weekly average, showing reduced liquidity.
Company Negative News
- Decline in DII holding (-0.94%) reflects reduced domestic institutional confidence.
- Profit contraction in latest quarter highlights margin pressure.
Company Positive News
- Increase in FII holding (+0.66%) shows growing foreign investor interest.
- Strong brand presence and diversified FMCG portfolio support long-term growth.
Industry
- FMCG sector remains resilient with steady demand.
- Industry P/E at 30.6 indicates growth orientation.
- Competitive landscape favors companies with strong distribution and brand equity.
Conclusion
⚖️ Jyothy Labs exhibits robust fundamentals with excellent return metrics, negligible debt, and sector resilience. Despite short-term profit decline and premium P/B valuation, the company remains a healthy mid-cap FMCG player. Entry around 240–255 ₹ is recommended for long-term investors seeking growth with stability.
Would you like me to also highlight technical support and resistance levels (based on DMA, RSI, and MACD) to complement this fundamental view?